On August 12, 2026, Coherus Oncology entered into a Loan and Security Agreement for a $55 million senior secured term loan (Tranche A) maturing in August 2031. The loan carries a floating interest rate of 4.15% plus the greater of the Prime Rate or 6.75%. On August 14, 2026, the company drew the full $55 million to repay its prior senior secured term loan (which matured in May 2029 and had a higher interest rate) and to fund working capital. The company also has options to draw additional tranches of $25 million and $20 million. The loan is secured by substantially all assets, including intellectual property. Coherus Oncology is a biotechnology company that develops and commercializes oncology therapeutics.
